Alcon Aandeel

Alcon Investeringen

De Totale Investeringen van Alcon (ALC.SW) per 12 aug 2026 bedraagt 214,00 Miljoen USD. In het voorgaande jaar bedroeg Totale Investeringen 611,23 Miljoen USD — een verandering van -64,99% (lager).

Investeringen

214,00 MiljoenUSD

YoY

-64,99%

Laatst bijgewerkt:

Totale Investeringen van Alcon is 2026 214,00 Miljoen USD. Totale Investeringen van Alcon was 2025 611,23 Miljoen USD. Het is daarmee -64,99% lager lager dan het jaar ervoor.
Access this data via the Eulerpool API

Alcon Aandelenanalyse

Wat doet Alcon? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Alcon

Totale Investeringen van Alcon bedraagt 214,00 Miljoen USD in 2026.

Totale Investeringen van Alcon is veranderd van 611,23 Miljoen USD naar 214,00 Miljoen USD, wat een verandering van -64,99% vertegenwoordigt. De waarde is lager dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Totale Investeringen Alcon sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Totale beleggingen omvatten zowel kortlopende als langlopende effecten die door een bedrijf worden aangehouden.

USD van Totale Investeringen is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — Alcon

Alle kengetallen — Alcon